Cargando…
Rivaroxaban for the treatment of cerebral venous thrombosis
BACKGROUND: New Oral Anticoagulants (NOACs) such as Rivaroxaban are introduced as alternatives to conventional vitamin-K antagonists in the long-term treatment of thrombotic events due to their lower bleeding risk. There is a lack of evidence on the effectiveness and safety of Rivaroxaban in Cerebra...
Autores principales: | Esmaeili, Sara, Abolmaali, Meysam, Aarabi, Sobhan, Motamed, Mohammad Reza, Chaibakhsh, Samira, Joghataei, Mohammad Taghi, Mojtahed, Mohammad, Mirzaasgari, Zahra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883416/ https://www.ncbi.nlm.nih.gov/pubmed/33588777 http://dx.doi.org/10.1186/s12883-021-02091-1 |
Ejemplares similares
-
Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD
por: Esmaeili, Sara, et al.
Publicado: (2021) -
Carotid intima-media thickness measurements in patients with multiple sclerosis
por: farzan, Marjan rahimi, et al.
Publicado: (2022) -
Acute disseminated encephalitis (ADEM) as the first presentation of COVID-19; a case report
por: Esmaeili, Sara, et al.
Publicado: (2022) -
Use of oral rivaroxaban in cerebral venous thrombosis
por: Maqsood, Muhammad, et al.
Publicado: (2020) -
The Role of Warfarin and Rivaroxaban in the Treatment of Cerebral Venous Thrombosis
por: Fayyaz, Muniba, et al.
Publicado: (2019)